Trial Profile
A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naive Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs JNJ 56914845 (Primary) ; Peginterferon alfa-2a; Ribavirin; Telaprevir
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 30 Sep 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 08 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
- 26 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.